3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Triple Negative Breast Neoplasms
4
Breast Neoplasms
4
Carcinoma, Non-Small-Cell Lung
3
Urinary Bladder Neoplasms
2
Uterine Cervical Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Metastatic Solid Tumors
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Glioblastoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Hepatocellular
1
Interventions
Rituximab
4
blinatumomab
3
Whole-Body Irradiation
3
Cyclophosphamide
3
fludarabine phosphate
2
Mycophenolic Acid
2
Melphalan
2
Lenalidomide
2
Clofarabine
2
treosulfan
1
thymoglobulin
1
sabatolimab
1
pembrolizumab
1
peginterferon alfa-2a
1
obinutuzumab
1
midostaurin
1
ixazomib
1
fludarabine
1
eribulin
1
daratumumab
1
acalabrutinib
1
Trastuzumab
1
Tacrolimus
1
Sodium Chloride
1
Sirolimus
1
Peripheral Blood Stem Cell Transplantation
1
Pentostatin
1
N,N-dicyclohexyl-isoborneol-10-sulfonamide
1
Methotrexate
1
Magnetic Resonance Imaging
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Neoplasm, Residual
×
sacituzumab govitecan
×
Clear all
No trials found.